Insys cannabidiol tagged an Orphan Drug


The FDA designates Insys Therapeutics' (INSY) pharmaceutical cannabidiol an Orphan Drug for the treatment of Lennox-Gastaut Syndrome, a severe form of childhood-onset epilepsy characterized by multiple seizure types, moderate-to-severe cognitive impairment and an abnormal EEG.

Orphan Drug designation affords the developer certain incentives including extended marketing exclusivity.

From other sites
Comments (1)
  • Doyee51986
    , contributor
    Comments (325) | Send Message
     
    GWPH & INSY for the win!
    25 Jun 2014, 05:25 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs